6 results on '"Patrick Serruys"'
Search Results
2. Patrick Serruys: holding open the options for stents
- Author
-
Serruys and P.
- Published
- 1997
- Full Text
- View/download PDF
3. Editorial.
- Author
-
Juillière, Yves, Cohen, Ariel, and Le Heuzey, Jean-Yves
- Abstract
Comme chaque année, la communauté cardiologique française, aux côtés de ses collègues des pays francophones du Maghreb, d’Afrique sub-saharienne et du Moyen-Orient, ainsi que d’Europe et d’Amérique du Nord, se donne rendez-vous à Paris, au Palais des Congrès, pour l’événement annuel dans notre spécialité, les 26es Journées Européennes de la Société Française de Cardiologie . Nous espérons que comme pour les éditions précédentes, l’innovation diagnostique et thérapeutique en pathologie cardiovasculaire sera au rendez-vous au travers des points forts habituels avec des séances à thème dont plus de trente sessions communes avec des sociétés savantes alliées, actualités sur les grands essais cliniques, ateliers pratiques, flashes d’actualité, communications originales orales ou affichées et commentées. Les horaires ont été un peu modifiés, dès 8h30 les jeudis et vendredis, avec une plage libre plus large à l’heure du déjeuner (12h-14h), octroyant donc une disponibilité accrue pour les activités organisées dans cette tranche horaire. Le programme sera mis en ligne de façon anticipée sur l’application smartphone dédiée, dès le mois d’août et mis à jour régulièrement. Nous aurons la chance lors de cette édition d’assister à des conférences de prestige. Eugène Braunwald sera en effet l’invité exceptionnel pour l’une des deux conférences américaines consacrée à l’avenir de notre spécialité. Il a marqué notre spécialité de son autorité scientifique et par ses qualités pédagogiques hors du commun. Mariell Jessup nous fera l’honneur de donner la 2 ème conférence américaine autour de son thème de prédilection, l’insuffisance cardiaque. Patrick Serruys sera l’orateur de la conférence européenne et parlera des stents biorésorbables. John Eikelboom, Patrizio Lancellotti, Roberto Lang et tant d’autres collègues venant de pays voisins éclaireront ces journées de leur expertise dans leur domaine d’intérêt, au côté de conférenciers français connus. La conférence Laënnec traditionnelle donnera l’occasion au Pr Alain Carpentier de mettre en perspective son expérience avec les avancées de l’exercice de notre art. Le thème des Journées Européennes de la Société Française de Cardiologie 2016 , « Cardiologie connectée » répondra, du moins nous l’espérons, à l’exigence de plus en plus mise en avant, de déterminer et d’orienter la démarche clinique au quotidien, au travers de ces outils connectés qui permettent de disposer en continu, d’informations précieuses sur les constantes vitales de nos patients. A côté de la détection à distance des arythmies cardiaques ou des dysfonctionnements des dispositifs implantables, les applications sont aujourd’hui multiples. D’autres domaines de la pathologie cardiovasculaire seront également concernés tels l’éducation thérapeutique du patient. Le village sera donc consacré à la cardiologie connectée, au travers de séances de cas pratiques et de rencontres avec les experts, sous la responsabilité de Jean Ferrières. L’enseignement par simulation sera également abordé, au travers des expériences de différents centres français. Les comités d’organisation et scientifique des Journées Européennes de la Société Française de Cardiologie ont œuvré cette année pour préparer un programme basé sur les dernières avancées cliniques et thérapeutiques dans les différents domaines de la pathologie cardiovasculaire et sur les recommandations consensuelles mises à jour régulièrement, chaque année, émanant de l’European Society of Cardiology. Nous avons souhaité mettre en avant, outre les communications libres ou affichées, les posters commentés sélectionnés et primés par un jury, qui seront présentés oralement samedi, juste avant la séance de remise des prix et bourses de la Société Française de Cardiologie. Un parcours dédié à nos plus jeunes collègues (cardiologues en formation) a été planifié, en déclinant les différents thèmes présentés de façon paritaire par nos collègues jeunes mais déjà expérimentés au côté de leurs maîtres. En partenariat avec l’industrie, et sous le contrôle du Comité indépendant de validation, les symposia et déjeuners-débats traiteront des avancées et des perspectives médicamenteuses et interventionnelles. Cette démarche sera complétée par des informations très pratiques apportées lors des « training centers » qui permettent de présenter dans un cadre convivial, avec des échanges non formels, les matériels les plus récents à visée tant diagnostique (imagerie cardiovasculaire en particulier), que thérapeutique (dispositifs), soulignant leur place croissante dans l’arsenal thérapeutique, ainsi que des innovations pharmacologiques. Parmi les évènements 2016, la conférence exceptionnelle sera assurée par Jean-Christophe Rufin, homme de lettres, neurologue, médecin du monde, ambassadeur de France, Académicien, Prix Goncourt, qui nous fera l’honneur de participer à nos journées, en nous instruisant et en nous éclairant. Les 26es Journées Européennes de la Société Française de Cardiologie ont donc l’ambition de renouveler et d’élargir le succès des éditions précédentes, qui ont réuni plus de 8 000 participants, dont l’assiduité et l’implication ne sont plus à prouver. L’organisation des 26es Journées Européennes de la Société Française de Cardiologie est chaque année un défi (faire plus vite pour être au plus près de l’actualité) et un pari (faire encore et toujours un peu mieux), relevés grâce à l’aide des comités d’organisation et scientifique, de l’ensemble du personnel de la Maison du Cœur et de l’implication de la société EUROPA Organisation. Tous sont à remercier pour cet effort particulier, qui demande une année de travail pour faire de ces journées, le succès que chaque édition précédente a rencontré. Bon congrès à tous ! [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Editorial.
- Author
-
Juillière, Yves, Cohen, Ariel, and Le Heuzey, Jean-Yves
- Abstract
As we do each year, the French Cardiology community, with our colleagues from Francophone countries, Europe, North America, and Africa, at our sides, meet at the Palais des Congrès for the annual event of our specialization, the 26th European Days of the French Society of Cardiology . We hope that this year, as for the precedent editions, diagnostic innovations and cardiovascular pathology therapeutics will be thoroughly represented throughout the meeting in the main sessions including more than thirty joint sessions with allied national societies, news flashes, updates of the leading clinical trials, practical workshops, original oral communications and commented poster presentations. This year, the timeline has been slightly modified, we will be starting at 8:30 a.m. on Thursday and Friday, leaving more free time at lunch (12 to 2 p.m.) and thus increasing the possibilities for the activities organized at this time. The program will be available online, in advance, on the dedicated smartphone application as of August and will be regularly updated. We will have the great fortune, at this edition, to attend presentations from numerous highly esteemed orators. Eugene Braunwald will be the honored speaker for one of the two American lectures dedicated to the future of cardiology. He has made significant contributions to our field through his scientific leadership and his exceptional pedagogy. Mariell Jessup will honor us by giving the second American lecture on her theme of excellence, heart failure. Patrick Serruys will be the European lecture orator and will address bioabsorbable stents. John Eikelboom, Patrizio Lancellotti, Roberto Lang and numerous other colleagues from neighboring countries, alongside the recognized French lecturers, will enlighten this year’s European Days with their insight in their fields of expertise. The traditional Laënnec lecture provides the occasion for a leader Alain Carpentier, MD, PhD, this year to share, from his own perspective, his experience in the advancements of the practice of our art. The theme of the European Days of the French Society of Cardiology 2016 , « E-Cardiology » responds, at least we hope it does, to the increasing foregrounded necessity to orient and tailor our daily clinical practice, through the integration of connection technology and devices, providing us with continuous and precious information on the vital signs of our patients. Alongside remote detection of cardiac arrhythmias and implantable device malfunctioning, there are numerous uses for these technologies today. Other domains of cardiovascular pathologies are equally concerned by this technology such as therapeutic education of patients. The village will be dedicated to this theme, with practical case sessions and meetings with experts, overseen by Jean Ferrières. Learning through simulation will also be addressed through the experiences of various French centers. The organizing and scientific committees of the European Days of the French Society of Cardiology have based the organization this year’s program on the most recent clinical and therapeutic advances across the numerous domains of cardiovascular pathologies and on the constantly updated consensus guidelines emanating from the European Society of Cardiology. Beyond the programmed communications, we wish to draw your attention to the commented posters that have been selected and awarded prizes by a jury, which will be orally presented on Saturday, just before the session in which prizes and scholarships will be awarded by the French Society of Cardiology. A program dedicated to our youngest colleagues, Cardiologists in training, has been planned, addressing these various themes presented on a joint basis between our young colleagues, who have already gained experience, and their seniors. In partnership with the industry, and under the supervision of the Independent Validation Committee, the symposia and lunch-debates will address medication and intervention advances and perspectives. This program will be completed by the very practical information provided at the “training center”, proposing a convivial environment enabling more candid exchanges about the most recent diagnostic material (cardiovascular imagery in particular) and therapeutics (both medications and devices), underlining their increasingly important place in the therapeutic arsenal. Among the events of 2016, the exceptional lecture will be given by Jean-Christophe Rufin, a man of letters, neurologist, “doctor of the world”, French Ambassador, and academic, Goncourt Prize, who will honor us with his participation in our European Days by sharing his knowledge and cultivating our understanding. The 26th European Days of the French Society of Cardiology aim to refresh and to continue expanding upon the success of prior editions, which have united more than 8,000 participants, as the attendance and implication have since been proven. The organization of the 26th European Days of the French Society of Cardiology is each year both a challenge (going faster in order to stay at the pace of the news) and a gamble (always doing a little bit better), and may be attributed to the aid of our organization and scientific committees, to the team at the Maison du Cœur, and to the implication of the EUROPA Society Organization. All are to be thanked for this very special effort, which requires a full year of work in order to make these European Days, the success that each prior year has known. Enjoy the congress! [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. STENTS.
- Abstract
The article reports on the findings of the study conducted by Dr. Patrick Serruys of the Erasmus University Hospital in Rotterdam, Netherlands regarding the bioabsorbable drug-eluting stent being developed by Abbott Laboratories Inc. According to the study, the stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years. The characteristics and functions of the product are described further.
- Published
- 2009
6. Abbott Labs Finally Turns Potential Into Profit.
- Author
-
James Brumley
- Abstract
Abbott Laboratories' (NYSE: ABT ) recent quarterly results may finally start to justify the stock's lofty valuation. In a nutshell, the company's first quarter revenue and earnings were outstanding. On a quarter-over-quarter basis, net income for the quarter ending March 31 rose 35% to $938 million on a 14% improvement in sales to $6.77 billion from $5.95 billion last year. Normally one quarter wouldn't sway me. Two good quarters and solid prospects, though, can get my attention. Abbot Catching Up To Its Valuation Abbott's stock price is a little bit inflated relative to its peers on a trailing-twelve-month basis. The company's price-to-earnings (P/E) ratio of 22, is nearly twice that of GlaxoSmithKline's (NYSE: GSK ) multiple of 11. It's more than double the valuation of pharmaceutical/diagnostic giant Novartis AG's 's (NYSE: NVS ) P/E ratio of 9. Point being, ABT shares could be considered expensive. But what if you just considered Abbott's last two quarters, which were considerably better than the previous three quarters? With net income of $1.2 billion in the last quarter of 2007 added to Q1's $938 million, the six-month net income total comes to $2.14 billion. On an annualized basis (multiplying it by 2) that's $4.28 billion and translates into a trading multiple of 18.7 for Abbott shares. Although this is only a thumbnail sketch, to me it illustrates progress. By the way, based on the stock's current price, the P/E ratio would be around 16 if Abbott Labs meets its outlook. (For related reading, see Is a stock with a lower P/E always a better investment? ) Sustainable Growth? One good quarter, or even two, doesn't mean much if it can't be reproduced going forward. Fortunately, Abbott will have Humira on its menu for a long while. The company attributes the bulk of the recent sales increase to rheumatoid arthritis treatment Humira. The drug's sales reached $878 million last quarter, up 54%. It's still only about 13% of the company's revenue-generating drugs though, so it's not like Abbott is a one-trick pony. Moreover, on Wednesday, Humira was approved for sale in Japan. That brings the total number of countries offering the drug up to 75. For the record, Japan also approved Swiss drug maker Roche's rheumatoid arthritis drug Actemra on Wednesday. The growth rate for all drugs in addition to the opening of new Humira markets suggest top and bottom line growth is sustainable. But, there's even more that could add a boost to Abbott's results. Heart Of The Matter Though still technically a speculation from an investor's viewpoint, Abbott's heart stent business could take off in the second quarter of this year. Stents are tubes inserted into arteries following angioplasty to help prop them open. There is some speculation that Abbott's newest version of the Xience stent will win the FDA's approval for use in the United States soon. The Xience stent is technology acquired when Abbott purchased part of Boston Scientific (NYSE: BSX ) last year. In clinical trials, the newest version of Xience (Xience V) stents are showing much better results compared to its major competition Taxus, according to Dr. Patrick Serruys, principal investigator of the stent clinical trials and Professor of Interventional Cardiology at Erasmus University Hospital Rotterdam. If approval goes through, Xience's superiority could be a boon for Abbott's shareholders. Abbott already has a foothold in the stent market, selling $189 million worth in Q1. These sales come from previously approved, older model stents, in the U.S. and newer Xience V stents on the market in several foreign locations. Bottom Line Despite Humira's growth prospects, the company's stent prospects, and the fact that the last two quarters have validated Abbott Labs' own outlook, the market still seems less than thrilled with the stock. However, the collective market isn't always right. Abbott recently reaffirmed its 2008 outlook, expecting earnings per-share to come in somewhere between ... [ABSTRACT FROM PUBLISHER]
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.